PL3183236T3 - Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma - Google Patents
Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psmaInfo
- Publication number
- PL3183236T3 PL3183236T3 PL15753692.1T PL15753692T PL3183236T3 PL 3183236 T3 PL3183236 T3 PL 3183236T3 PL 15753692 T PL15753692 T PL 15753692T PL 3183236 T3 PL3183236 T3 PL 3183236T3
- Authority
- PL
- Poland
- Prior art keywords
- psma
- tracer
- preparation
- production
- active esters
- Prior art date
Links
- 150000002148 esters Chemical class 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000700 radioactive tracer Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14182053 | 2014-08-24 | ||
| EP14183635.3A EP2993171A1 (en) | 2014-09-04 | 2014-09-04 | Method for the production of 18F-labeled PSMA-specific PET-tracers |
| PCT/EP2015/069356 WO2016030329A1 (en) | 2014-08-24 | 2015-08-24 | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3183236T3 true PL3183236T3 (pl) | 2022-07-18 |
Family
ID=53938345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15753692.1T PL3183236T3 (pl) | 2014-08-24 | 2015-08-24 | Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10112974B2 (pl) |
| EP (1) | EP3183236B1 (pl) |
| ES (1) | ES2912753T3 (pl) |
| PL (1) | PL3183236T3 (pl) |
| WO (1) | WO2016030329A1 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ583931A (en) | 2007-08-17 | 2012-06-29 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| KR102575825B1 (ko) | 2012-11-15 | 2023-09-06 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
| SG11201602249RA (en) | 2013-10-18 | 2016-05-30 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EA035171B1 (ru) | 2013-11-14 | 2020-05-08 | Эндосайт, Инк. | Конъюгаты на основе связывающихся с psma лигандов или ингибиторов psma для позитронно-эмиссионной томографии |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| HRP20210183T1 (hr) | 2015-09-30 | 2021-04-30 | Deutsches Krebsforschungszentrum | 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate |
| GB201518918D0 (en) | 2015-10-26 | 2015-12-09 | Norsk Medisinsk Syklotronsenter As And Uni I Oslo | Method |
| KR20220063298A (ko) * | 2016-03-22 | 2022-05-17 | 더 존스 홉킨스 유니버시티 | 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 |
| LT3481804T (lt) | 2016-06-10 | 2025-02-25 | The Johns Hopkins University | Radioaktyviai pažymėto prostatos specifinio membranos antigeno (psma) inhibitoriaus [18f]dcfpyl pagerinta sintezė |
| US20190151483A1 (en) * | 2016-07-25 | 2019-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof |
| CN109803973B (zh) | 2016-08-10 | 2022-05-24 | 癌靶技术有限责任公司 | 螯合psma抑制剂 |
| AU2017348111B2 (en) | 2016-10-27 | 2023-04-06 | Progenics Pharmaceuticals, Inc. | Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications |
| DE102016122273B4 (de) | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Präkursoren für die Radiofluorierung |
| WO2018098390A1 (en) * | 2016-11-23 | 2018-05-31 | Cancer Targeted Technology Llc | Albumin-binding psma inhibitors |
| US11628229B2 (en) * | 2017-03-13 | 2023-04-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of synthesizing 18F radiolabeled biomolecular agents |
| JP2020522506A (ja) * | 2017-05-30 | 2020-07-30 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤 |
| EP3765097B1 (en) | 2018-03-16 | 2022-04-27 | Universität zu Köln | 2-alkoxy-6-[18f]fluoronicotinoyl substituted lys-c(o)-glu derivatives as efficient probes for imaging of psma expressing tissues |
| BR112020020961A2 (pt) | 2018-04-17 | 2021-01-19 | Endocyte, Inc. | Métodos de tratamento de câncer |
| TWI872062B (zh) | 2019-04-24 | 2025-02-11 | 美商普吉尼製藥公司 | 用於偵測轉移之骨掃描影像之自動及互動式分析系統、裝置及方法 |
| CN120097929A (zh) | 2019-05-20 | 2025-06-06 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| US12417533B2 (en) | 2019-09-27 | 2025-09-16 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| KR20230009399A (ko) * | 2020-05-11 | 2023-01-17 | 더 스쿨 코포레이션 칸사이 유니버시티 | 화합물 및 그의 제조방법, 산발생제, 조성물, 레지스트막, 하층막, 패턴 형성방법, 및 광학물품 |
| CN111548305B (zh) * | 2020-05-12 | 2021-08-31 | 北京师范大学 | 一种可用于靶向psma的喹啉类化合物及其制备方法 |
| CN114671806B (zh) * | 2022-04-08 | 2024-03-01 | 上海如絮生物科技有限公司 | 一种亲水性吡啶衍生物、中间体、其制备方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3699162B1 (en) | 2006-11-08 | 2022-06-29 | Molecular Insight Pharmaceuticals, Inc. | Heterodimers of glutamic acid |
| EP2921482B1 (en) | 2007-06-26 | 2018-09-05 | The Johns Hopkins University | Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| EP2062630A1 (en) | 2007-11-20 | 2009-05-27 | Trasis S.A. | Method for the direct elution of reactive 18F fluoride from an anion exchange resin in an organic medium by the use of strong organic bases |
| HUE034027T2 (en) | 2008-08-01 | 2018-01-29 | Univ Johns Hopkins | Psma-binding agents and uses thereof |
| CA2755965C (en) | 2009-03-19 | 2019-04-16 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| GB0905438D0 (en) * | 2009-03-30 | 2009-05-13 | Ge Healthcare Ltd | Radiolabelling reagents and methods |
-
2015
- 2015-08-24 ES ES15753692T patent/ES2912753T3/es active Active
- 2015-08-24 EP EP15753692.1A patent/EP3183236B1/en active Active
- 2015-08-24 PL PL15753692.1T patent/PL3183236T3/pl unknown
- 2015-08-24 US US15/506,351 patent/US10112974B2/en active Active
- 2015-08-24 WO PCT/EP2015/069356 patent/WO2016030329A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2912753T3 (es) | 2022-05-27 |
| EP3183236A1 (en) | 2017-06-28 |
| WO2016030329A1 (en) | 2016-03-03 |
| US10112974B2 (en) | 2018-10-30 |
| EP3183236B1 (en) | 2022-04-20 |
| US20170267717A1 (en) | 2017-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3183236T3 (pl) | Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma | |
| IL250511A0 (en) | Crystalline forms of ibrutinib | |
| IL249968A0 (en) | Preparation of a test site | |
| HUE042409T2 (hu) | Eljárás diaril-tiohidantoin vegyület elõállítására | |
| SG10201601042PA (en) | Production of ester mixtures | |
| IL249663A0 (en) | Process for the preparation of substituted oxiranes and triazoles | |
| HUP1400475A2 (en) | Novel process for preparation of treprostinil and its salts | |
| PL3199161T3 (pl) | Preparat farmaceutyczny | |
| ZA201605103B (en) | Administration of tasimelteon under fasted conditions | |
| HUE042349T2 (hu) | Eljárás diariltiohidantoin vegyület elõállítására | |
| PL3110249T3 (pl) | Sposób wytwarzania mikrokapsułek biobójczych | |
| PL3189045T3 (pl) | Nowe sole nilotynibu i jego polimorfy | |
| ZA201707704B (en) | Production of vcl4 | |
| IL252461B (en) | Alpha-asrylaldehyde ester, a method for its preparation and application | |
| SG11201505385VA (en) | Pharmaceutical composition in the form of a tabletand a method for producing same | |
| SG11201608422VA (en) | Phenanthroline phosphonic acid derivative and preparation method therefor and application thereof | |
| EP3181125C0 (en) | CAPSULE FORMULATION | |
| IL249130A0 (en) | Preparation of piperidine-4-carbthioamide | |
| EP3221320A4 (en) | A process for the preparation of ibrutinib | |
| PL2977373T3 (pl) | Sposób katalitycznego wytwarzania estrów | |
| IL237572A0 (en) | Process and intermediates for the preparation of dastinib | |
| IL251099A0 (en) | A salt of phenylglycine methyl ester | |
| GB2544228B (en) | Production Method of Joint Material | |
| LT3393246T (lt) | Chelanto gamybos būdas | |
| TWM490349U (en) | Improved structure of a darter |